Ron Orlando is an Professor at the Complex Carbohydrate Research Center with joint positions in the Departments of Chemistry and Biochemistry & Molecular Biology at the University of Georgia. He has over 20 years experience in analysis of biomolecules by mass spectrometry. His primary areas of expertise are in the fields of proteomics and glycomics, and has extensive experience with the technical aspects of both, including the current software, and the needs of scientists performing proteomic and glycomic research. Ron received his Ph.D. in chemistry from the University of Delaware and performed his postdoctoral research at the University of Maryland under Dr. Catherine Fenselau. Prior to moving to UGA, Ron directed the mass spectrometry facility at the Suntory Institute for Biorganic Research in Osaka Japan. He has also been a consultant for the biotech company Ciphergen Biosystems, Inc. Dr. Orlando has authored over 90 peer reviewed publications in the proteomic and glycomic fields, co-invented numerous U.S. patents, and routinely serves on the National Institutes of Health review panels.

Rick Tarleton is a Distinguished Research Professor at the University of Georgia and the founder and former director of the UGA Center for Tropical and Emerging Global Diseases.  His primary research focus is the immunobiology of Chagas disease, a fatal parasitic infection caused by the protozoan parasite, Trypanosoma cruzi.  In his 24 years at UGA, Rick has generated more than $15 million in research funding for his laboratory, published more than 80 peer reviewed articles and holds 2 patents on the technical advances in diagnosis and prevention of T. cruzi infection.  Rick received his Ph.D. from Wake Forest University and performed postdoctoral studies at the University of Rochester Cancer Center.  He holds appointments in the departments of Cellular Biology, Microbiology, and Infectious Disease at the University of Georgia.  Most recently Dr. Tarleton is founder and president of The Chagas Disease Foundation, a non-profit organization established to promote the diagnosis, control, prevention, and treatment of Chagas disease.

Scot Weinberger is the president and founder of GenNext Technologies, Inc. Prior to establishing GenNext, Scot served as Director of Research Proteomics at Ciphergen Biosystems, Inc. (Fremont, CA); MALDI Product Manager for the Hewlett Packard Company (Palo Alto, CA); Vice President of Research and Development for Linear Scientific Inc. (Reno, NV); Capillary Electrophoresis R/D Group Leader for Spectra Physics, Inc. (San Jose, CA); and Application's Manager for Linear Instruments (Reno, NV). Weinberger is a renowned, inventive technical leader in bioresearch instrumentation and has numerous patents in these disciplines along with many publications and presentations. Scot served as a panel reviewer for numerous NIH/NCI grant programs including NIBIB SBIR/STTR, Innovative Molecular Analysis Technology (IMAT), and Ovarian/Breast Cancer Specialized Programs of Research Excellence (SPORE).

Brian Musselman, Ph.D.  is currently Chief Operating Officer of IonSense®, Inc a leading producer of DART® Technology. Brian is also President of SciMarket Strategies, Inc, a technology market development company that specializes in design and implementation of early stage product evaluations. Formerly, Dr.  Musselman was the Worldwide Marketing Director for Biospectrometry at the PerSeptive Biosystems Division of Applied BioSystems. Prior to that he served as worldwide marketing director for JEOL Ltd. Before joining JEOL, Brian was managing director of the Michigan State University Mass Spectrometry Core Facility, an analytical chemist at CPC, Inc and Faberge International. Brian received his Ph.D. from Michigan State University.

Barry Boyes has over 18 years experience in new product creation in analytical chemistry, biochemistry, and molecular biology. Previously, Boyes was R&D manager for the consumables and biochemicals product lines, including proteomics and gene expression products for Agilent Technologies, Inc. Boyes was also a Senior Scientist and Program Leader for Rockland Technologies, Inc., where he was integral in the development and commercialization of the Zorbax products. He received his Ph.D. from the University of British Columbia and has authored more than thirty peer-reviewed publications as well as over twenty patent applications.